Dr Gennaro Sardella (Sapienza University of Rome, Rome, Italy) discusses data from the Onyx ONE study and its implications for clinical practice.
The Onyx ONE study is a randomised controlled trial with Resolute Onyx™ DES in one month dual antiplatelet therapy (DAPT) for high-bleeding risk patients.
1. What are the Onyx ONE study aims?
2. Could you describe this study design and the technology used?
3. Can you summarise the main findings to date?
Filmed on location at JIM 2020.
Interviewer: Ashlynne Merrifield
Videographer: Dom Woodruff